fashion -WSS

fashion

author：focus 2025-10-02 09:47:22 - browse：6957

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： ASCO: AstraZeneca's hat trick, and palliative care's spotlight

WSS

Pfizer plans to depart BIO

Leukemia patients are helped by Syndax's new type of therapy

Ultragenyx gene therapy for rare liver ailment succeeds in late

Chemotherapy shortages won’t get better under Biden’s latest plan

What PEPFAR has meant on the ground in Ukraine

See how much Covid

knowledge

fashion

entertainment

In Memoriam: Notable people who died in 2023

Patients' immediate access to test results puts radiologists in a bind

Apple is now the first public company to be valued at $3 trillion

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Moonlake's readout produced a cash windfall. Risks remain

NIH documents show early flaws of $1.6 billion long Covid program

Peter Hotez and the public health issue of online harassment

Change Healthcare can notify patients about the breach, HHS says

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

focus

HIV drugs protect against transmission, even in unprotected sex

Kaiser's Risant Health gobbled up Geisinger. Who is next?

With trial win, GSK could get blood cancer drug back on market

Leukemia patients are helped by Syndax's new type of therapy

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Roche to buy Carmot Therapeutics, developer of obesity drugs

knowledge

explore

explore

hotspot